By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TiGenix 

Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70


SEARCH JOBS


Industry
Biotechnology






Company News
TiGenix Announces Top-Line Phase I/II Results Of AlloCSC-01 In Acute Myocardial Infarction 3/13/2017 7:51:41 AM
TiGenix Announces Positive Topline Week-104 Data For Cx601 ADMIRE-CD Trial 3/9/2017 7:16:23 AM
TiGenix Receives Positive Feedback From The FDA On Cx601 Global Phase III Trial Protocol 3/7/2017 7:49:00 AM
TiGenix Provides Update On Cx601 Marketing Authorization Application Procedure In Europe 3/6/2017 9:03:45 AM
TiGenix To Present At Cowen and Company's 37th Annual Health Care Conference In Boston 3/1/2017 9:21:07 AM
Takeda (TKPYY) And TiGenix Report New Data Highlighting Maintenance Of Long-Term Remission Of Complex Perianal Fistulas In Crohn’s Disease Patients With Cx601 2/17/2017 6:39:00 AM
TiGenix Announces Acceptance Of Cx601 Abstract For Oral Presentation At 12th Congress Of ECCO 2/6/2017 8:38:55 AM
TiGenix Enrolls First Patient iIn Phase Ib/IIa Clinical Trial Of Cx611 In Severe Sepsis 1/31/2017 10:09:36 AM
Takeda (TKPYY) Notifies 4.48% Shareholding In TiGenix 1/9/2017 9:51:41 AM
TiGenix: Notice In Relation To The Convertible Bonds Due 2018 12/27/2016 9:48:32 AM
12345678910...
//-->